Paul D'Angio
Director/Board Member at NEXIMMUNE, INC.
Net worth: 6 244 $ as of 2024-03-30
Profile
Paul D'Angio is an Independent Director at NexImmune, Inc. He was previously a Senior VP & Global Head-Technical Operations at Celgene Corp.
and a Vice President & Head-Development at Edge Therapeutics, Inc. He also served as Vice President & Head-Manufacturing at PDS Biotechnology Corp.
Mr. D'Angio received his undergraduate degree from Duquesne University of The Holy Spirit and his graduate degree from Seton Hall University School of Law.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NEXIMMUNE, INC.
0.09% | 2023-10-30 | 1,113 ( 0.09% ) | 6 244 $ | 2024-03-30 |
Paul D'Angio active positions
| Companies | Position | Start |
|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 2016-12-31 |
Former positions of Paul D'Angio
| Companies | Position | End |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Corporate Officer/Principal | 2020-05-31 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Corporate Officer/Principal | 2019-02-28 |
| CELGENE | Corporate Officer/Principal | - |
Training of Paul D'Angio
| Duquesne University of The Holy Spirit | Undergraduate Degree |
| Seton Hall University School of Law | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NEXIMMUNE, INC. | Health Technology |
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Health Technology |
- Stock Market
- Insiders
- Paul D'Angio
